Switching and combining of dopamine agonists

Journal of Neurology, Supplement

Volumn 251, Issue 6, 2004, Pages

  Junghanns, Susann ^a   Glöckler, Theresa ^a   Reichmann, Heinz ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Combining of dopamine agonists; Dopamine agonists; Parkinson's disease; Switching of dopamine agonists; Treatment

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HALLUCINATION; HUMAN; LEG EDEMA; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; VALVULAR HEART DISEASE; VOMITING;

DOPAMINE AGONISTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; PARKINSONIAN DISORDERS; TREATMENT OUTCOME;

EID: 5644220292     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-1605-7     Document Type: Conference Paper

References (32)

1. Ahlskop JE (2003) Slowing Parkinson's disease progression. Recent dopamine agonist trials. Neurology 60:381-389
2. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 109:489-502
3. Canesi M, Antonini A, Mariani CB, Tesei S, Zecchinelli AL, Barichella M, Pezzoli G (1999) An overnight switch to ropinirole therapy in patients with Parkinson's disease. J Neural Transm 106:925-929
4. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine- phentermine. N Engl J Med 337:581-588
5. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11:58-65
6. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O (2000) Sleep attacks and Parkinson's disease treatment. Lancet 355:1333-1334
7. Flaherty KR, Bates JR (1996) Mitral regurgitation caused by chronic ergotamine use. Am Heart J 131:603-606
8. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908-1910
9. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P (2003) Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110:1119-1127
10. Gerlach M, Reichmann H, Riederer P (2003) Die Parkinson Krankheit. Springer, Wien New York, pp 88-89
11. Goetz CG, Blasucci L, Stebbins GT (1999) Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology 52:1227-1229
12. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord 19:656-662
13. Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacol 35:1503-1519
14. Korczyn AD, Thalamas C, Adler CH (2002) Dosing with ropinirole in a clinical setting. Acta Neurol Scand 106:200-204
15. Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK (1999) Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 74:371-375
16. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J, Newman-Tancredi A (2002) Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804
17. Müngersdorf M, Sommer U, Sommer M, Reichmann H (2001) High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm 108:1309-1317
18. Oertel WH (2000) Pergolide vs Levodopa (PELMOPET). Mov Disord 15(Suppl 3):M86. Data presented at the 6th International Congress of Parkinson's Disease and Movement Disorders (Barcelona, Jun 11-15, 2000)
19. Olanow CW (2002) The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 58(Suppl 1):33-41
20. Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR (2001) A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 108:71-77
21. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 284:1931-1938
22. Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH (2002) Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72:713-720
23. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491
24. Reichmann H, Herting B, Müller A, Sommer U (2003) Switching and combining dopamine agonists. J Neural Transm 110:1393-1400
25. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 (Suppl 1):23-30
26. Schapira AH (2000) Sleep attacks (sleep episodes) with pergolide. Lancet 355:1332-1333
27. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334-336
28. Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S (2003) Dual dopamine agonist treatment in Parkinson's disease. J Neurol 250:822-826
29. Todman DH, Oliver WA, Edwards RL (1990) Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin Exp Neurol 27:79-82
30. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004): Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179-1183
31. th International Symposium on Parkinson's Disease, Rome. New Trends Clin Neuropharmacol 8:280
32. Whone AJ, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl AJ, Watts RL, Brooks DJ (2002) The REAL-PET-Study: Slower progression in early Parkinson's disease treated with Ropinirole compared with L-Dopa. Neurology 58:A82-A83